fashion -WSS

fashion

author：comprehensive 2025-09-30 05:03:56 - browse：4

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Hepatitis C has a cure — but many Americans still lack access to it

WSS

As pharma fights Medicare drug negotiation, hospitals, docs silent

AstraZeneca bets AAV gene therapy will still deliver the goods

Apple is now the first public company to be valued at $3 trillion

Medicare details structure of new drug price negotiation program

In science, is the line between industry and academia shifting?

Radiation, mainstay of cancer treatment, begins a fade

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Bright Health sells Medicare Advantage business to Molina

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Medicare details structure of new drug price negotiation program

Bright Health sells Medicare Advantage business to Molina

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How to make AI work for medicine

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Heart attack and stroke risk calculators need revising

In Memoriam: Notable people who died in 2023

Feds fine Medicare Advantage plans for overcharging members

Wikipedia

What do new weight loss drugs mean for bariatric surgery?

AstraZeneca challenges Medicare drug negotiation program

Diversity in medical illustrations gets boost from Chidiebere Ibe

Radiation, mainstay of cancer treatment, begins a fade

What AAP's gender

Neuroscience startup Neumora files for IPO

leisure time

hotspot

knowledge

focus